Shuttle Pharmaceuticals Holdings
NASDAQ: SHPHGaithersburg, US · Founded 2018 · Delaware corporation
Shuttle Pharmaceuticals operates Molecule.ai, an AI-driven software platform for molecular discovery and early-stage drug development. The platform helps researchers explore chemical space and evaluate molecular candidates to support decision-making in the earliest stages of drug development.
Founders & leadership
Shuttle Pharmaceuticals Holdings was founded in 2018 by Mira Jung and Anatoly Dritschilo.
MJ
Mira JungChief Scientific Officer for Biology
AD
Anatoly DritschiloChief Executive Officer and Chairman
MV
Michael Vander HoekVice President - Operations and Regulatory
TR
Tyvin RichinChief Medical Officer
TL
Timothy LorberinChief Financial Officer
PD
Peter DritschiloinChief Operating Officer2012–2025
Board
AH
Amir HeshmatpourBoard director
JS
Joshua SchaferBoard director
CS
Chris SenanayakeBoard director
SR
Steven RichardsBoard director
BJ
Bette JacobsBoard director
MB
Milton BrownBoard director
Reported raises · per SEC filings
Form D private placements$23.4M disclosed across 9 rounds · 2018–2026
▶$10MraisedMay 2026 · 47 investors · Other TechnologyRule 506(b)
▶$10MraisedMay 2026 · 47 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Ryan TrasoliniExecutive Officer
- Adam ChambersDirector
- Yuying LiangExecutive Officer
- George ScorsisDirector
- Angel LirianoDirector
- Christopher CooperExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $10M
- Sales commissions
- $1M
- Placement agents
- E.F. Hutton & Co.
- First sale
- Apr 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedNov 2025 · 1 investors · PharmaceuticalsRule 506(b)
▶$2.5MraisedNov 2025 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Christopher CooperExecutive Officer, Director
- Tyvin RichExecutive Officer
- Adam ChambersDirector
- Mira JungExecutive Officer
- Angel LirianoDirector
- Sachin PathigodaDirector
- George ScorsisDirector
- Timothy LorberExecutive Officer
- Oleh NabytDirector
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- Sales commissions
- $100K
- Placement agents
- WestPark Capital, Inc.
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.3MraisedJun 2025 · 1 investors · PharmaceuticalsRule 506(b)
▶$4.3MraisedJun 2025 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Mira JungExecutive Officer
- Tyvin RichExecutive Officer
- George ScorcisDirector
- Timothy LorberExecutive Officer
- Steven RichardsDirector
- Joseph TungDirector
- Peter DritschiloExecutive Officer
- Christopher CooperExecutive Officer
- Oleh NabytDirector
- Offering amount
- $4.3M
- Amount sold
- $4.3M
- Sales commissions
- $170K
- Placement agents
- WestPark Capital, Inc.
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$790KraisedOct 2024 · 5 investors · PharmaceuticalsRule 506(b)
▶$790KraisedOct 2024 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Joshua SchaferDirector
- Chris SenanayakeDirector
- Michael Vander HoekExecutive Officer
- Steven RichardsDirector
- Tyvin RichExecutive Officer
- Timothy LorberExecutive Officer
- Mira JungExecutive Officer
- Bette JacobsDirector
- Anatoly DritschiloExecutive Officer, Director
- Milton BrownDirector
- Peter DritschiloExecutive Officer
- Offering amount
- $1.3M
- Amount sold
- $790K
- Minimum investment
- $95K
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedJan 2023 · 1 investors · PharmaceuticalsRule 506(b)
▶$4MraisedJan 2023 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Mira JungExecutive Officer
- Milton BrownDirector
- Steven RichardsDirector
- Michael Vander HoekExecutive Officer
- Anatoly DritschiloExecutive Officer, Director
- Joshua SchaferDirector
- Chris SenanayakeDirector
- Bette JacobsDirector
- Peter DritschiloExecutive Officer
- Tyvin RichExecutive Officer
- Offering amount
- $4M
- Amount sold
- $4M
- Minimum investment
- $4M
- Sales commissions
- $320K
- Placement agents
- Boustead Securities, LLC
- First sale
- Jan 2023
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$125KraisedAug 2022 · 3 investors · PharmaceuticalsRule 506(b)
▶$125KraisedAug 2022 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Anatoly DritschiloExecutive Officer, Director
- Joshua SchaferDirector
- Mira JungExecutive Officer
- Steven RichardsDirector
- Michael Vander HoekExecutive Officer
- Chris SenanayakeDirector
- William AdkinsDirector
- Milton BrownExecutive Officer, Director
- Peter DritschilloExecutive Officer
- Tyvin RichExecutive Officer
- Offering amount
- $500K
- Amount sold
- $125K
- Minimum investment
- $25K
- Sales commissions
- $12.5K
- Placement agents
- Boustead Securities, LLC
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$365KraisedFeb 2022 · 11 investors · PharmaceuticalsRule 506(b)
▶$365KraisedFeb 2022 · 11 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- William AdkinsDirector
- Mira JungExecutive Officer
- Michael Vander HoekExecutive Officer
- Steven RichardsDirector
- Chris SenanayakeDirector
- Joshua SchaferDirector
- Anatoly DritschiloExecutive Officer, Director
- Milton BrownExecutive Officer, Director
- Tyvin RichExecutive Officer
- Peter DritschilloExecutive Officer
- Offering amount
- $2M
- Amount sold
- $365K
- Minimum investment
- $25K
- Sales commissions
- $36.5K
- Placement agents
- Boustead Securities, LLC
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$500KraisedJan 2022 · 2 investors · PharmaceuticalsRule 506(b)
▶$500KraisedJan 2022 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Steven RichardsDirector
- William AdkinsDirector
- Anatoly DritschiloExecutive Officer, Director
- Mira JungExecutive Officer
- Michael Vander HoekExecutive Officer
- Milton BrownDirector
- Peter DritschiloExecutive Officer, Director
- Josh SchaferDirector
- Chris SenanayakeDirector
- Tyvin RichExecutive Officer
- Offering amount
- $500K
- Amount sold
- $500K
- Minimum investment
- $250K
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 7
by search overlapTipRanks13 shared keywordsFinancial analysis and stock research platform.
TradingView13 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Seeking Alpha13 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
trefis12 shared keywordsTrefis operates thinkHub, a data-driven investment analytics platform that uses what it calls "Understandable-AI" — an auditable, non-black-box decision system — to build and run equity portfolios (such as its High-Quality, Bayesian, and Reinforced Value strategies) aimed at outperforming the S&P 500. It serves investors and money managers, offering peer comparisons, valuation, and macro-event analyses, with practical investing carried out via an affiliated firm.
Robinhood12 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Perplexity11 shared keywordsAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
StockTwits10 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Companies competing with Shuttle Pharmaceuticals Holdings for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Major Investor Makes Bold Move With Shuttle Pharmaceuticals Stock - TipRanks.comtipranks.com · Jul 2026
Shuttle Pharma posts $2.2M Q1 loss, flags cash risk | SHPH Quarterly Report (10-Q)stocktitan.net · May 2026Frequently asked questions
- What does Shuttle Pharmaceuticals Holdings do?
- Shuttle Pharmaceuticals operates Molecule.ai, an AI-driven software platform for molecular discovery and early-stage drug development. The platform helps researchers explore chemical space and evaluate molecular candidates to support decision-making in the earliest stages of drug development.
- Who founded Shuttle Pharmaceuticals Holdings?
- Shuttle Pharmaceuticals Holdings was founded by Mira Jung, Anatoly Dritschilo in 2018.
- How much funding has Shuttle Pharmaceuticals Holdings raised?
- Shuttle Pharmaceuticals Holdings has disclosed $23.4M raised across 9 rounds.
- Where is Shuttle Pharmaceuticals Holdings headquartered?
- Shuttle Pharmaceuticals Holdings is headquartered in Gaithersburg, US.